Document Detail

Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B.
MedLine Citation:
PMID:  12140382     Owner:  NLM     Status:  MEDLINE    
The challenge to find a reliable tumour marker for the management of melanoma patients still remains. In this study, the serum L-dopa/L-tyrosine ratio was compared with serum S100B as a reference marker. A total of 89 melanoma patients were sampled and staged according to the American Joint Committee on Cancer (AJCC) classification. Of these, 19 stage III and 28 stage IV patients were evaluated for disease progression at 1.5 years and 6 months post-sampling, respectively. Serum L-dopa and L-tyrosine were measured by high performance liquid chromatography (HPLC) (normal value for ratio < 16 x 10(-5)) and S100B using the LIA-mat Sangtec 100 assay (normal value < 0.10 microg/l). Non-parametric tests (Kruskal-Wallis analysis of variance, Dunn's and Spearman) were used for the statistical analysis. The median serum L-dopa/L-tyrosine ratio was 16.0 x 10(-5) (range 2.7-545.1 x 10-5 and the median S100B level was 0.15 microg/l (range < 0.10-13.8 microg/l), with a sensitivity of 51% for the ratio and 66% for S100B. There was a 47% discordance and no correlation between the two markers (r = 0.149). The ratio was higher in stage IV than in other stages (P < 0.05), as was the S100B level (P < 0.0001). Both markers were higher in patients with evolutive disease (n = 23) than in stable patients (n = 24), with values of 20.8 x 10(-5) versus 13.1 x 10(-5) for the ratio (P < 0.05) and 0.89 microg/l versus 0.16 microg/l for S100B (P < 0.001); for the ratio, this difference was more pronounced in stage III than in stage IV patients. The overall sensitivity and specificity of the markers to predict disease progression were 78% and 67%, respectively, for the ratio, and 74% and 83%, respectively, for S100B (using an ROC cut-off of 0.38 microg/l). In conclusion, the serum L-dopa/L-tyrosine ratio correlates with melanoma progression and has predictive value, especially in stage III patients. This tumour marker, like S100B, could serve as an additional tool in the management of melanoma.
K Stoitchkov; S Letellier; J-P Garnier; B Bousquet; N Tsankov; P Morel; G Ghanem; T Le Bricon
Publication Detail:
Type:  Comparative Study; Evaluation Studies; Journal Article    
Journal Detail:
Title:  Melanoma research     Volume:  12     ISSN:  0960-8931     ISO Abbreviation:  Melanoma Res.     Publication Date:  2002 Jun 
Date Detail:
Created Date:  2002-07-25     Completed Date:  2003-01-30     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9109623     Medline TA:  Melanoma Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  255-62     Citation Subset:  IM    
Department of Dermatology, National Center of Oncology, Plovdivsko pole Street No. 6, Sofia 1756, Bulgaria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Bulgaria / epidemiology
Chromatography, High Pressure Liquid
Disease Progression
Follow-Up Studies
Levodopa / blood*
Melanoma / blood*,  mortality,  pathology
Middle Aged
Neoplasm Proteins / blood*
Neoplasm Staging
Nerve Growth Factors
Predictive Value of Tests
S100 Proteins / blood*
Skin Neoplasms / blood*,  mortality,  pathology
Tumor Markers, Biological / blood*
Tyrosine / blood*
Reg. No./Substance:
0/Levodopa; 0/Neoplasm Proteins; 0/Nerve Growth Factors; 0/S-100 calcium-binding protein beta subunit; 0/S100 Proteins; 0/Tumor Markers, Biological; 55520-40-6/Tyrosine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years' experience.
Next Document:  Frequent downregulation of Fas (CD95) expression and function in melanoma.